Project Grant R43CA232977

Summary of Federal Grant Award Embiosys Inc. received a $2.76 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the development and clinical evaluation of a novel therapeutic device combining capecitabine chemotherapy with wearable induced electric field (IEF) therapy for triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB2/3). The award, obligated on September 17, 2025, with completion targeted for...

This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

Blood Cell Technologies LLC received a $400,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on September 1, 2025, with completion targeted for August 31, 2026. The award funds development of second-generation BLVRB (biliverdin IXB reductase) inhibitors designed to treat chemotherapy-induced thrombocytopenia (CIT), a dose-limiting toxicity affecting approximately 50% of chemotherapy patients with hematologic malignancies...

Federal Grant Award Summary Biotex, Inc. received a $1.3 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded September 18, 2025, with completion targeted for August 31, 2027. The award funds development and clinical translation of the OncoMagnetic Device (OMTX), a non-invasive, wearable therapeutic device that uses spinning oscillating magnetic fields to...

This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...

Federal Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 19, 2025, with a completion date of August 31, 2029. The award funds development and clinical translation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform that leverages CRISPR-based biosensing to detect cancer biomarkers...

Syntr Health Technologies, Inc. received a $356,500 Project Grant awarded on September 2, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and commercialization of the SYNTRFUGE system and SYNTRFPU360 platform—FDA-cleared tissue processing technologies designed to rapidly process large volumes of tissues for clinical and research applications. The platform enables dissociation of cancer tumor tissue into single...

Federal Grant Award Summary Zeest Bio Inc. received a $400,000 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on September 15, 2025, with completion targeted for August 31, 2026. The company is developing a novel liver-specific Positron Emission Tomography (PET) tracer designed to improve cancer detection capabilities beyond current imaging modalities. The primary deliverable is completion of preclinical testing...